APLAR 2024 | YHLO Leads a New Chapter in APS
The 26th Asia Pacific League of Associations for Rheumatology (APLAR) Congress was held from August 21 to 25, 2024, in Singapore. This prestigious event drew nearly 2,000 delegates from over 60 countries, covering regions such as the Asia-Pacific, the Middle East, Europe, and North America, and brought together the world's leading scholars in rheumatology and immunology. Among the highlights of this international medical event, YHLO's academic symposium stood out as a shining beacon.
Under the theme "The Dawn of a New Era in Antiphospholipid Syndrome," YHLO's symposium gathered the leading figures in global rheumatology, sparking a wave of academic exchange. The session was co-chaired by Prof. Xiaofeng Zeng, Director of the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID) at the Chinese Academy of Medical Sciences & Peking Union Medical College, and Prof. Qijing Li, Chief Innovation Officer at the Institute of Molecular and Cell Biology (IMCB), Singapore, and Adjunct Professor of Immunology at the National University of Singapore. Prof. Zeng emphasized the symposium is a critical opportunity to advance international collaboration in the field of antiphospholipid syndrome (APS), while Prof. Li encouraged global unity to drive progress in rheumatology and immunology.
The symposium featured several renowned experts. Prof. Yuichiro Fujieda from Hokkaido University Hospital, Prof. Jiuliang Zhao from Peking Union Medical College Hospital, and Prof. Haiyan Lin from Sun Yat-sen Memorial Hospital of Sun Yat-sen University delivered captivating and insightful presentations.
Prof. Yuichiro Fujieda's presentation, titled "Diagnosis and Management of Antiphospholipid Syndrome," provided a comprehensive overview of the latest diagnostic criteria and management strategies for APS, focusing on the clinical application of the 2023 ACR/EULAR guidelines and the clinical value of antiphospholipid antibodies (aPLs). Prof. Jiuliang Zhao outlined ten key principles for managing APS, covering the systemic nature of APS, its diverse clinical manifestations, risk factors associated with thrombotic events, different predictive models for arterial and venous events, the importance of recognizing microvascular lesions, and personalized treatment strategies. He also shared the latest progress from the Chinese APS multicenter cohort registry study. Prof. Haiyan Lin discussed the clinical value of both standard and non-standard aPLs in pathological pregnancies, aiming to optimize personalized treatment plans for obstetric APS patients.
The symposium saw participation from over 400 rheumatology experts and scholars from around the world, including presidents of rheumatology associations from Europe, the Middle East, Asia-Pacific, and other regions. The experts engaged in lively discussions, raising questions and exploring topics such as cutting-edge APS research, clinical challenges, and strategies to overcome them.
Prof. Tsutomu Takeuchi, President of the Japan College of Rheumatology and current APLAR President, extended his heartfelt congratulations on the success of YHLO's symposium. He expressed his hope for more academic exchange activities with YHLO in the future to further deepen global research collaboration in autoimmune diseases.
This symposium not only showcased YHLO's global academic innovation and influence but also energized advancements in the field and international cooperation. As a pioneer in China's autoimmune disease sector, YHLO has actively promoted APS research, collaborating with several authoritative domestic institutions, including Fuwai Hospital of the Chinese Academy of Medical Sciences and Nanfang Hospital of Southern Medical University, to conduct multicenter studies on aPLs in acute myocardial infarction and pathological pregnancy. In 2022, YHLO and Peking Union Medical College Hospital jointly launched the "Chinese Antiphospholipid Syndrome Multicenter Cohort Registry Study (CAPSTONE)," aiming to establish the largest APS cohort in China and globally, and to amplify China's voice in the field of aPLs research.
This academic feast was not only an exchange of knowledge but also marked another milestone in YHLO's deepening collaboration with the global medical community. Through this conference, YHLO has once again demonstrated its leadership in the field of autoimmune diseases and reaffirmed its commitment to collaborating with top international experts and academic institutions. Looking ahead, YHLO will continue to uphold the principles of innovation-driven progress and win-win cooperation, pushing research in APS and other fields to new heights, bringing more hope to patients worldwide, and achieving even greater academic accomplishments.
Attachments:
MORE NEWS
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
